The Anti-Cancer Properties of Cannabidiol and
Δ-9Tetrahydrocannabinol in Haematological
Malignancies In Vitro
Volume 5 - Issue 1
Pier Paolo Piccaluga1-4*, Serah Kaggia3, Emily Rogena3, Nicholas A Abinya4, Shaymaa Khattab5, Ashraf Elghandour5, Manal Elsorady5, Nicoletta Testoni1, Giuseppe Visani6
- 1Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna School of Medicine, Institute of Hematology and Medical Oncology “L. and A. Seràgnoli”, Italy
- 2Istituto Euro-Mediterraneo di Scienza e Tecnologia (IEMEST) Palermo, Italy
- 3Department of Pathology, School of Medicine, Jomo Kenyatta University of Agriculture and Technology, Juja, Kenya
- 4Nairobi Hospital and University of Nairobi, Nairobi, Kenya
- 5Hematology Unit, internal medicine department, Faculty of Medicine, Alexandria University, Egypt
- 6Hematology and Stem Cell Transplantation, AORMIN, Pesaro, Italy
Received: November 11, 2021 Published: December 2, 2021
Corresponding author: Pier Paolo Piccaluga, Department of Experimental, Diagnostic, and Specialty Medicine University of Bologna, Italy; Institute of Hematology and Medical Oncology “L&A Seràgnoli”, Via Massarenti, 9 -40138 Bologna, Italy
DOI: 10.32474/OAJOM.2021.05.000205
Fulltext
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
A 69-year-old man came at our observation for thrombocytosis. Peripheral blood counts showed: PLT, 805x109/L; hemoglobin 14.4 g/dl; WBC, 7x109/L (with 58% neutrophils, 27% lymphocytes, 12% monocytes, 2% eosinophils, and 1% basophils). Bone marrow examination at trephine biopsy showed a hypercellular marrow with an obvious megakaryocytopoiesis increase (Figure 1). Some of the megakaryocytes were small, with a reduced ploidy. The karyotype, assessed as previously described [8,9] showed an isolated inv(2)(p13;q14). The patient did not record any previous thrombosis or hemorrhage. Clinically, the disease remained stable, the PLT count being 750 x109/L, at the time of writing after 6 years of hydroxyurea treatment, at the daily dosage of 1000 mg p.o. No thrombotic or hemorrhagic event was reported during the follow-up.
Introduction|
Acknowledgment|
References|